31results about "C-reactive protein" patented technology

The use of inhibitors of long pentraxin PTX3 for the preparation of a medicament for the prevention and treatment of autoimmune diseases and of degenerative diseases of bone and cartilage is described.

An aptamer specifically binding to C-reactive protein (CRP) is provided. The aptamer includes a following nucleotide sequence: 5′-angngggngnntgnnt-3′, wherein n is a nucleotide selected from a, t, c and g.

Described herein are homing polypeptides that home to atherosclerotic plaque(s) in mammals and nucleic acids that encode such polypeptides. Also described are methods for detecting and treating conditions or disorders associated with, or characterized, by elevated levels of homing polypeptides that home to atherosclerotic plaque and / or vulnerable plaque.

The present invention provides a biomarker for detecting and diagnosing polypoidal choroidal vasculopathy (PCV) of human eyes, including levels of hyperhomocysteinemia that are identified, wherein elevated levels of hyperhomocysteinemia are highly associated with PCV of the human eyes. In addition, the present invention further provides a method for detecting and diagnosing PCV of the human eyes.

The application provides methods for determining a patient's risk for developing fibrosis or a fibrosis-related disorder. Concentrations of C reactive protein (CRP) and serum amyloid protein (SAP) are measured from a biological sample to determine the SAP-to-CRP ratio. This ratio can then be compared with one or more SAP-to-CRP reference ratios to determine a patient's risk for developing a fibrosis related disorder. The diagnostic methods can also be used to determine the severity of fibrosis in a patient afflicted with such a disease. Furthermore, methods for treating patients having a fibrosis-related disorder are provided. For example, a patient that has a lower SAP-to-CRP ratio than one or more reference values may be treated with an SAP agonist and / or CRP antagonist to treat or prevent a fibrosis disorder. The methods may further comprise determining the R131 / H131 polymorphism of FcγRIIA as a risk factor for developing fibrosis or a fibrosis-related disorder.

The invention belongs to the biotechnological field, and provides a polypeptide. The polypeptide includes two dominant antigen epitopes of the recombinant canine C-reactive protein (CRP). The polypeptide is coupled with the KLH protein for enhancing the immune effect. The invention provides a canine CRP recombinant protein. The canine CRP recombinant protein mainly includes the two dominant antigen epitopes. Specific to the aim of increasing the yield of the recombinant protein in a prokaryotic expression system, the recombinant protein amino acid sequence is converted into a corresponding nucleotide sequence by using an escherichia coli preferred codons, the nucleotide sequence is subjected to chemical synthesis, and the recombinant protein expression vector is built. The invention further relates to the preparation of the recombinant protein mono-clone antibody, the mono-clone antibody is prepared by antigen immunization, cell fusion and a plurality of screening, the mono-clone antibody is purified, the fluorescent microsphere is marked respectively, the best mono-clone pair determined through orthogonal experiment, the recombinant canine C-reactive protein can be applied to diagnosis of inflammation.

Disclosed are a highly efficient method for production of heterologous proteins performed by utilizing microorganisms, as well as fusion proteins, and an antiserum. The method includes a method for production of a protein (A) in the form of a fusion protein, comprising the steps of (a) preparing a DNA which codes for a fusion protein comprising the peptide chain forming the protein (A) and the C-terminal peptide or its fragment (B) of the Cry proteins produced by Bacillus thuringiensis, and (b) introducing the DNA into a host bacterium to transform the same, and (c) allowing the fusion protein to be expressed in the transformed host bacterium, as well as a method for production of the protein (A) itself comprising a further step of removing the peptide chain (B) from the fusion protein obtained.

The invention discloses a composite quality control product based on multiple diagnostic marker-specific epitope polypeptide molecules linked by ferritin nanoparticle carriers and a preparation method thereof. Through antibody detection and epitope analysis techniques, most of the The dominant epitope of the diagnostic marker protein is located, and then linked to the ferritin molecule by connecting esters to form a "Fer-Linker-Epitope Peptide" complex, and the synthetic gene sequence of the complex is transferred into the prokaryotic large intestine through a specific vector Bacillus recombinant expression, so that the composite antigen (quality control product) containing the dominant epitope polypeptide molecules of multiple diagnostic markers can be detected by multiple diagnostic reagents at the same time. The quality control product of the invention has high detection efficiency, low cost and excellent stability, and can be stored stably for a long time under the condition of 2-8°C.

The invention relates to the use of a citrate solution for affinity-chromatographic removal of C-reactive protein (CRP) from biological fluids, wherein the CRP is affinity-chromatographically removed using (Ca2+-dependent) binding of CRP to a column material functionalized with ω-phosphonooxyalkyl ammonium groups and / or with ω-ammoniumalkoxy-hydroxy-phosphoryloxy groups.